Chief Executive Officer
Jim serves as Chief Executive Officer and a member of the Board of Directors for MedLumics bringing 30 years of extensive operational experience in medical device design, development, and commercialization.
Prior to joining MedLumics, Jim served as Partner in Seroba Life sciences Limited, a Dublin based venture capital firm. Jim is a serial entrepreneur founding multiple medical device start-ups in the cardiovascular field serving as CEO of Verso Technologies, Inc., Apica Cardiovascular Ltd., Advanced Medical Technologies, Inc. (APK), and MitralSolutions, Inc. Earlier in his career, Jim held Director level positions at global medical device companies such as Medtronic, AVE, and Guidant.
Jim holds a B.A. degree from Furman University, Greenville, S.C. and served in the United States Military following graduation for 7 years.
VP of Clinical and Regulatory affairs
Christophe holds multiple academic degrees including, an engineering degree from the Université de Technologie de Compiègne in France, an MSc in blood transfusion and immunology, a PhD in immuno-biotechnologies and an MBA from ESSEC in Paris, France. He is has been co-author in numerous scientific publications and patent.
Christophe started his career in a French biotech startup affiliate of the National Blood Transfusion Foundation in the late 80s. Then He spent 5 years in Germany as a research and quality assurance manager in a young CRO, PRA International. He then spent 5 years in the clinical development field for Cardiac Rhythm Management at Ela Medical, which was part of Sorin Group. From 2002 to 2014 he was based in Belgium as the VP of Clinical Affairs and Health Economics of the International Division at St. Jude Medical covering all product lines CRM, Atrial Fibrillation, Cardiac Surgery, Interventional Cardiology and Neuromodulation.
Then He joined the Executive Committee of Mauna Kea Technologies, world leader in endomicroscopy, as VP Clinical and Regulatory Affairs, Health Economics and Market Access and Corporate Compliance Officer based in Paris, France.
VP, Research & Development and Manufacturing
Robert has a proven history of managing medical device projects from concepts to commercialization with extensive experience in leading research and development teams across a wide breath of medical specialties and technologies.
Prior to Medlumics, Robert was the VP of Research and Development at Devoro Medical where he led Quality, Operations and product development of the WOLF Thrombectomy device, which was acquired by Boston Scientific; the VP of Research & Development at Three Rivers Medical where he led Quality, Operations and product development of the RIO neurovascular mechanically detachable embolization coil; the Senior Director of Research & Development for Baxano Inc. managing the development of Spinal Decompression tools for treatment of Spinal Stenosis; and the Director of Research & Development for Barrx Medical, managing the development of radiofrequency ablation devices for treating Barrett’s Esophagus disease.
Robert honed his skills at Boston Scientific, spending 14 years in various leadership and product development roles. Robert holds a B.S. in Mechanical Engineering from the University of Massachusetts at Lowell. He also more than 200 combined issued patents and published U.S. patent applications, as well as numerous International patents and applications.
Lucía accumulates more than 10 years’ experience in banking, international controllership and financial management of high-growth technology start-ups. Previous positions of Financial Manager for Small and Medium Enterprises in “la Caixa” and Financial leader in Integromics’ group. She also holds significant experience within Public funding, National and European programs, FP7, H2020, and she is expert for H2020 since 2019.
Lucía Colmenero holds a degree in Business Administration, with a major in Finance, a MBA and a Master in Finance and accumulates a wide experience in spin-off creation and growth from her position as Technical Project Manager in the Company Start-up Support Unit of the Spanish National Research Council (CSIC), and also from her academic experience in the study of key economical factors for the creation of spin-off companies.
She contributes to fund-raising activities resulting in a 34,4M€ in private investments in 2017 .